

*Errata***Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans**A. Vella<sup>2</sup>, P. Shah<sup>2</sup>, A. S. Reed<sup>2</sup>, A. S. Adkins<sup>2</sup>, R. Basu<sup>2</sup>, R. A. Rizza<sup>1, 2</sup><sup>1</sup> Mayo Clinic and Foundation, Rochester, USA<sup>2</sup> Department of Internal Medicine, Division of Endocrinology, Metabolism and Nutrition, Mayo Clinic and Foundation, Rochester, USA**Diabetologia (2002) 45:1410–1415**

The authors identified several errors after their paper had been printed:

1. C-peptide values were inadvertently converted to nmol/l from ng/ml by multiplying by 0.331 twice. Correct values require division of reported values by 0.331.
2. Fig. 2: the Y-axis for growth hormone should be labelled as µg/l.
3. The mean growth hormone concentration at 0 min on the saline study day was incorrectly plotted. The correct value was 2.34 µg/l +/- 1.64.
4. Fig. 2: the Y-axis for cortisol should be labelled as nmol/l

Published online: 31 October 2003

© Springer-Verlag 2003

DOI 10.1007/s00125-003-1250-1

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-002-0924-4>

*Corresponding author:* R. A. Rizza, Mayo Clinic and Foundation, 200 1st Street SW, Rm 5-194 Joseph, Rochester, MN 55905, USA

E-mail: rizza.robert@mayo.edu

**Trends in hypertension management in Type I diabetes across Europe, 1989/1990 – 1997/1999**S. S. Soedamah-Muthu<sup>1, 2</sup>, H. M. Colhoun<sup>2</sup>, H. Abrahamian<sup>3</sup>, N. N. Chan<sup>2</sup>, R. Mangili<sup>4</sup>, G. P. Reboldi<sup>5</sup>, J. H. Fuller<sup>2</sup>, the EURODIAB Prospective Complications Study Group<sup>1</sup> EURODIAB, Department of Epidemiology and Public-Health, Royal Free and University College London Medical School, London, UK<sup>2</sup> Department of Epidemiology and Public-Health, Royal Free and University College London Medical School, London, UK<sup>3</sup> Medical department, Hospital Vienna Lainz, Vienna, Austria<sup>4</sup> Divisions di Medicina, Istituto Scientifico San Raffaele, Milan, Italy<sup>5</sup> Dipartimento di Medicina Interna e Scienze, Endocrine e Metaboliche, Perugia, Italy**Diabetologia (2002) 45:1362–1371**

In the footnote of Table 2, the last item in this table “Controlled” should be indicated with the letter “f”, meaning “Proportion of treated hypertensives”.

Published online: 2 October 2003

© Springer-Verlag 2003

DOI 10.1007/s00125-003-1210-9

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00125-002-0914-6>

*Corresponding author:* S. S. Soedamah-Muthu, EURODIAB, Department of Epidemiology and Public-Health, Royal Free and University College London Medical School, 1–19 Torrington Place, London, WC1E 6BT, UK,  
E-mail: sabita@public-health.ucl.ac.uk